Open an account

Urogen Pharma

URGN · NASDAQ

$35.01+$0.86 (+2.52%)TodayMarket closed ·
Prev close $34.15

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Employees
298
Headquarters
Ra'anana
Listed
May 4, 2017
Sector
Health Care
Industry
Biotechnology
Website
urogen.com

URGN key statistics

Market cap
1.71B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.01M
Volume
747.78K
Open price
$34.05
High today
$35.70
Low today
$34.00
52 Week high
$50.81
52 Week low
$16.37

Urogen Pharma (URGN) at a glance

As of Oct 20, 2026, Urogen Pharma (URGN) shares are priced at $35.01, giving the company a market cap of 1.71B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $34.00 and $35.70. The current price is 3.0% above the day's low and 1.9% below its high.

Volume so far is 747.78K shares, below the average of 1.01M shares a day.

Over the past year Urogen Pharma has ranged from $16.37 to $50.81, and now sits 54% of the way up that range.

Urogen Pharma met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.2929.

The average analyst price target is $61.20, 74.8% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $61.20
Low
$48.48
Now
$35.01
High
$78.75

URGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 11.3% on average.

  1. Q3 FY24: reported -$0.55 per share against an estimate of -$0.8335
  2. Q4 FY24: reported -$0.80 per share against an estimate of -$0.7344
  3. Q1 FY25: reported -$0.92 per share against an estimate of -$0.816
  4. Q2 FY25: reported -$1.05 per share against an estimate of -$0.8504
  5. Q3 FY25: reported -$0.69 per share against an estimate of -$0.7064
  6. Q4 FY25: reported -$0.54 per share against an estimate of -$0.5125
  7. Q1 FY26: reported -$0.47 per share against an estimate of -$0.4922
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.2929

URGN news

  • Press releasePRNewswire

    IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

  • UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

  • Earnings Scheduled For November 6, 2025

  • Press releaseGlobe Newswire

    UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

  • Press releaseGlobe Newswire

    UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

  • Press releaseGlobe Newswire

    UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

  • Press releaseGlobe Newswire

    URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action

  • Press releaseGlobe Newswire

    UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm

Similar companies

Companies in the same industry as Urogen Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.